Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.00
+0.04 (0.45%)
Aug 13, 2026, 4:00 PM EDT - Market closed
Vir Biotechnology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 278.73 | 232.19 | 222.95 | 241.58 | 848.63 | 347.82 |
Short-Term Investments | 254 | 234.83 | 682.4 | 1,281 | 1,553 | 360.33 |
Cash & Short-Term Investments | 532.73 | 467.02 | 905.35 | 1,522 | 2,402 | 708.15 |
Cash Growth | -12.09% | -48.42% | -40.53% | -36.62% | 239.20% | -3.90% |
Other Receivables | - | - | - | - | - | 773.08 |
Total Trade Receivables | - | - | - | - | - | 773.08 |
Other Current Assets | 41.01 | 47.07 | 137.11 | 65.82 | 117.04 | 81.6 |
Total Current Assets | 573.74 | 514.08 | 1,042 | 1,588 | 2,519 | 1,563 |
Net Property, Plant & Equipment | 109.82 | 117.72 | 122.86 | 167.2 | 188.17 | 130.05 |
Other Intangible Assets | 7.7 | 7.85 | 8.12 | 22.57 | 32.76 | 33.29 |
Goodwill | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 |
Long-Term Investments | 475.02 | 314.58 | 190.02 | 105.28 | 23.93 | 201.39 |
Other Long-Term Assets | 31.59 | 31.66 | 18.42 | 18.86 | 21.23 | 9.78 |
Total Assets | 1,215 | 1,003 | 1,399 | 1,919 | 2,802 | 1,954 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 17.75 | 9.8 | 5.08 | 6.33 | 6.42 | 6.52 |
Accrued Expenses | 77.21 | 83.01 | 98.52 | 104.22 | 489.09 | 236.51 |
Unearned Revenue | - | - | - | 64.85 | 15.52 | 98.21 |
Other Current Liabilities | - | - | 16.06 | - | - | - |
Total Current Liabilities | 94.96 | 92.82 | 119.66 | 175.41 | 511.03 | 341.24 |
Long-Term Leases | 84.14 | 89.05 | 90.14 | 111.67 | 123.84 | 133.56 |
Other Long-Term Liabilities | 53.22 | 55.68 | 38.63 | 41.74 | 89.26 | 47.62 |
Total Long-Term Liabilities | 137.35 | 144.73 | 128.77 | 153.42 | 213.1 | 181.18 |
Total Liabilities | 232.31 | 237.55 | 248.43 | 328.82 | 724.13 | 522.42 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 2,230 | 1,965 | 1,912 | 1,829 | 1,710 | 1,572 |
Accumulated Other Comprehensive Income | -4.6 | -2.06 | -1.72 | -0.82 | -9.12 | -1.1 |
Retained Earnings | - | - | - | -237.82 | 377.24 | -138.6 |
Shareholders' Equity | 2,226 | 1,963 | 1,910 | 1,590 | 2,078 | 1,432 |
Total Liabilities & Equity | 1,215 | 1,003 | 1,399 | 1,919 | 2,802 | 1,954 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 84.14 | 89.05 | 90.14 | 111.67 | 123.84 | 133.56 |
Net Cash (Debt) | 448.59 | 377.96 | 815.21 | 1,411 | 2,278 | 574.58 |
Net Cash Growth | -12.49% | -53.64% | -42.21% | -38.08% | 296.50% | -14.28% |
Net Cash Per Share | 3.02 | 2.73 | 5.98 | 10.52 | 16.90 | 4.31 |
Book Value | 2,226 | 1,963 | 1,910 | 1,590 | 2,078 | 1,432 |
Book Value Per Share | 14.98 | 14.17 | 14.02 | 11.86 | 15.41 | 10.73 |
Tangible Book Value | 2,201 | 1,938 | 1,885 | 1,551 | 2,028 | 1,382 |
Tangible Book Value Per Share | 14.81 | 13.99 | 13.84 | 11.56 | 15.05 | 10.35 |